JP2017503798A5 - - Google Patents

Download PDF

Info

Publication number
JP2017503798A5
JP2017503798A5 JP2016544672A JP2016544672A JP2017503798A5 JP 2017503798 A5 JP2017503798 A5 JP 2017503798A5 JP 2016544672 A JP2016544672 A JP 2016544672A JP 2016544672 A JP2016544672 A JP 2016544672A JP 2017503798 A5 JP2017503798 A5 JP 2017503798A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
skin
compound according
skin disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016544672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017503798A (ja
JP6448651B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2015/050062 external-priority patent/WO2015112081A1/en
Publication of JP2017503798A publication Critical patent/JP2017503798A/ja
Publication of JP2017503798A5 publication Critical patent/JP2017503798A5/ja
Application granted granted Critical
Publication of JP6448651B2 publication Critical patent/JP6448651B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016544672A 2014-01-23 2015-01-22 皮膚病の処置のためのベンゾオキサジノン誘導体 Active JP6448651B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1430003 2014-01-23
SE1430003-2 2014-01-23
PCT/SE2015/050062 WO2015112081A1 (en) 2014-01-23 2015-01-22 Benzoxazinone derivatives for treatment of skin diseases

Publications (3)

Publication Number Publication Date
JP2017503798A JP2017503798A (ja) 2017-02-02
JP2017503798A5 true JP2017503798A5 (enExample) 2018-02-15
JP6448651B2 JP6448651B2 (ja) 2019-01-09

Family

ID=53681747

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016544672A Active JP6448651B2 (ja) 2014-01-23 2015-01-22 皮膚病の処置のためのベンゾオキサジノン誘導体

Country Status (18)

Country Link
US (2) US9695194B2 (enExample)
EP (1) EP3097085B1 (enExample)
JP (1) JP6448651B2 (enExample)
CN (1) CN106132941B (enExample)
AU (1) AU2015209761B2 (enExample)
CA (1) CA2934025C (enExample)
CY (1) CY1123477T1 (enExample)
DK (1) DK3097085T3 (enExample)
ES (1) ES2820868T3 (enExample)
HR (1) HRP20201500T1 (enExample)
HU (1) HUE051296T2 (enExample)
LT (1) LT3097085T (enExample)
PL (1) PL3097085T3 (enExample)
PT (1) PT3097085T (enExample)
RS (1) RS60830B1 (enExample)
SI (1) SI3097085T1 (enExample)
SM (1) SMT202000557T1 (enExample)
WO (1) WO2015112081A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112081A1 (en) * 2014-01-23 2015-07-30 Sixera Pharma Ab Benzoxazinone derivatives for treatment of skin diseases
US10306885B2 (en) 2015-05-13 2019-06-04 Nihon Nohyaku Co., Ltd. Anthranilic acid ester compound or salt thereof, agricultural and horticultural microbicide comprising the compound, and method for using the microbicide
EP3402572B1 (en) * 2016-01-13 2022-03-16 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
KR20200021991A (ko) * 2017-06-16 2020-03-02 아지트라 인코포레이티드 Lekti 발현 재조합 미생물을 사용하는 네테르톤 증후군의 치료를 위한 조성물 및 방법
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
US12360103B2 (en) 2018-04-20 2025-07-15 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
GB201809378D0 (en) 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis
BR112022004972A2 (pt) 2019-09-18 2022-06-28 Genentech Inc Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
JP2022551583A (ja) * 2019-10-01 2022-12-12 モレキュラー スキン セラピューティクス,インコーポレイティド Klk5/7デュアル阻害剤としてのベンゾキサジノン化合物
GB202001447D0 (en) * 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
BR102020009679A2 (pt) 2020-05-14 2021-11-23 Fundação Universidade Federal Do Abc - Ufabc Anticorpos recombinantes humanos para inibição da calicreína tecidual humana 7 (klk7) e uso em doenças relacionadas ao processo de descamação da pele
TW202304890A (zh) * 2021-04-14 2023-02-01 美商百歐克斯製藥公司 Klk5雙環雜芳香族抑制劑
EP4346761A1 (en) 2021-06-01 2024-04-10 Sixera Pharma AB Oil-in-water emulsion of 6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,l-benzoxazin-4-one

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB115399A (en) * 1917-03-28 1918-04-29 Reginald Guley Lewis Improved Delivery mechanism for Coin-freed Apparatus and the like.
GB1153994A (en) * 1965-07-21 1969-06-04 Aspro Nicholas Ltd Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them
AU2826099A (en) 1998-03-24 1999-10-18 Novo Nordisk A/S Heterocyclic compounds regulating clotting
WO2004108139A2 (en) 2003-06-06 2004-12-16 Arexis Ab Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
TWI419884B (zh) 2010-06-24 2013-12-21 Univ Chang Gung 苯并雜氧嗪酮衍生物,其製備方法以及包含有此等衍生物的藥學組成物
WO2015112081A1 (en) * 2014-01-23 2015-07-30 Sixera Pharma Ab Benzoxazinone derivatives for treatment of skin diseases

Similar Documents

Publication Publication Date Title
JP2017503798A5 (enExample)
JP2014521735A5 (enExample)
CY1123460T1 (el) Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης
RU2017105353A (ru) Соединения
CA2925624C (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
MX2016001361A (es) Compuestos terapeuticamente activos y sus metodos de uso.
HRP20201500T1 (hr) Derivati benzoksazinona za liječenje kožnih oboljenja
WO2016065226A8 (en) Indole carboxamides compounds useful as kinase inhibitors
RU2017112747A (ru) Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции
EA201792066A1 (ru) Оптимизированная комбинированная терапия и ее применение для лечения злокачественной опухоли и аутоиммунного заболевания
JP2012046524A5 (enExample)
JP2014511892A5 (enExample)
JP2017524735A5 (enExample)
JP2015513557A5 (enExample)
MX384234B (es) Uso de pridopidina para el tratamiento de enfermedad de huntington.
NZ726366A (en) Syk inhibitors
JP2016510326A5 (enExample)
ME02841B (me) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
MX374944B (es) Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria.
HK1209341A1 (zh) 與治療柏金遜症相關之運動與動作障礙副作用之治療
JP2019516739A5 (enExample)
JP2015521195A5 (enExample)
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
WO2016004413A3 (en) Gls1 inhibitors for treating disease
JP2015516419A5 (enExample)